Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models
Open Access
- 23 July 2004
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (9) , 633-641
- https://doi.org/10.1038/sj.cgt.7700745
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Focus on pancreas cancerCancer Cell, 2002
- Thyroid cell transformation requires the expression of the HMGA1 proteinsOncogene, 2002
- Adenovirus-mediated transfer of p53 and p16INK4a results in pancreatic cancer regression in vitro and in vivoGene Therapy, 2001
- Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trialGene Therapy, 2001
- Pancreatic CancerDrugs, 2000
- The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude miceGene Therapy, 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- HOW CELLS RESPOND TO INTERFERONSAnnual Review of Biochemistry, 1998
- Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-CNature, 1995
- Pancreatic CarcinomaNew England Journal of Medicine, 1992